Related Experiment Video
Updated: Mar 10, 2026
09:04
Activation and Measurement of NLRP3 Inflammasome Activity Using IL-1β in Human Monocyte-derived Dendritic Cells
Published on: May 22, 2014
21.5K
NLRP3 is Required for Complement-Mediated Caspase-1 and IL-1beta Activation in ICH
Sheng-Tao Yao1, Fang Cao1, Jia-Lin Chen2
1Department of Cerebrovascular Disease, The First Affiliated Hospital of Zunyi Medical College, No. 139, Dalian Avenue, Huichuan District, Zunyi, Guizhou, 563000, China.
Journal of Molecular Neuroscience : MN
|December 10, 2016
Summary
Complement-mediated inflammation drives neuroinflammation after intracerebral hemorrhage (ICH). NLRP3 inflammasome activation is crucial for this process, making it a potential therapeutic target for reducing brain damage.
Area of Science:
- Neuroscience
- Immunology
- Pathology
Background:
- Complement-mediated inflammation is a key driver of brain damage in intracerebral hemorrhage (ICH).
- Interleukin-1beta (IL-1β) is a critical pro-inflammatory factor implicated in ICH pathogenesis.
- The Nod-like receptor (NLR) family pyrin domain-containing 3 (NLRP3) inflammasome is a central regulator of inflammatory responses.
Purpose of the Study:
- To investigate the role of NLRP3 inflammasome activation in complement-mediated neuroinflammation following ICH.
- To determine the impact of NLRP3 inhibition on inflammatory markers, brain edema, and neurological deficits in an ICH model.
- To elucidate the interplay between complement activation and NLRP3 inflammasome signaling in ICH.
Main Methods:
- Intracerebral hemorrhage (ICH) model in mice.
- Western blot and dual immunofluorescence staining to assess NLRP3 and Iba-1 expression.
- Enzyme-linked immunosorbent assay (ELISA) to quantify IL-1β and IL-18 levels.
- Measurement of brain water content and neural deficit scores.
- Inhibition of NLRP3 inflammasome using small interfering RNAs (siRNAs).
- Complement activation studies using normal rabbit complement (NRC) and lipopolysaccharide (LPS).
Main Results:
- Complement components C3a and C5a were upregulated post-ICH, and C3 deficiency attenuated IL-1β release.
- NLRP3 inflammasome activation was observed in microglial cells in a time-dependent manner after ICH.
- Inhibition of NLRP3 (siNLRP3) and ASC (siASC) significantly reduced IL-1β, IL-18, caspase-1-p20, brain water content, and improved behavioral outcomes.
- Complement supplementation enhanced ICH-induced IL-1β release, whereas NLRP3 and ASC inhibition attenuated this effect.
Conclusions:
- Complement-induced neuroinflammation in ICH is dependent on NLRP3 inflammasome activation.
- NLRP3 plays a critical role in facilitating both LPS- and ICH-induced neuroinflammation.
- Targeting the NLRP3 inflammasome represents a promising therapeutic strategy for mitigating brain injury in ICH.
